Continuous Glucose Monitoring Devices Market Report 2025

This Continuous Glucose Monitoring Devices market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The continuous glucose monitoring devices market size has grown rapidly in recent years. It will grow from $8.41 billion in 2024 to $9.86 billion in 2025 at a compound annual growth rate (CAGR) of 17.22%. The growth during the historic period can be attributed to factors such as enhanced patient safety and improved health outcomes, a growing demand for diabetes management devices, greater usage of CGM devices, an increase in diabetes cases, and rising patient trust in these devices.

The continuous glucose monitoring devices market size is expected to see rapid growth in the next few years. It will grow to $18.45 billion in 2029 at a compound annual growth rate (CAGR) of 16.96%. The anticipated growth in the forecast period is driven by factors such as increased healthcare spending, heightened awareness about diabetes management, a rise in the number of diabetes cases, and the growing popularity of continuous glucose monitoring devices. Key trends in the forecast period include advancements in technology, innovations in CGM systems, mergers and acquisitions, regulatory approvals, and partnerships and collaborations.

The growing prevalence of diabetes is expected to drive the expansion of the continuous glucose monitoring devices market. Diabetes is a condition where the body cannot properly regulate blood sugar levels, either due to insufficient insulin production or insulin resistance. The increasing rates of diabetes are primarily attributed to factors such as poor diets, sedentary lifestyles, obesity, aging populations, and genetic predispositions. Continuous glucose monitoring (CGM) devices aid in managing diabetes by providing real-time data on blood glucose levels, enabling timely treatment adjustments and lifestyle changes. For example, in March 2024, the Office for Health Improvement & Disparities, a UK-based government department, reported that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes rose by 22%, while for type 2 diabetes, it increased by 21%. Additionally, the percentage of patients achieving target HbA1c levels reached 37.9%, the highest ever recorded in the National Diabetes Audit (NDA). As a result, the rising prevalence of diabetes is significantly contributing to the growth of the continuous glucose monitoring devices market.

Leading companies in the continuous glucose monitoring devices market are focused on developing innovative technologies, such as over-the-counter continuous glucose monitors, to improve accessibility, accuracy, and usability for individuals managing blood glucose levels. An over-the-counter CGM device allows users to continuously monitor their blood glucose levels without the need for a prescription. For instance, in September 2024, Abbott Laboratories, a US-based medical device company, launched the Lingo continuous glucose monitoring system. This device provides users with real-time glucose data, offering continuous monitoring and instant feedback on blood sugar levels throughout the day. It features a sleek design with easy-to-read displays and integrates with mobile apps for tracking trends and receiving alerts.

In September 2023, Abbott Laboratories, a US-based medical device company, acquired Bigfoot Biomedical Inc. for an undisclosed amount. This acquisition allows Abbott to enhance its diabetes care offerings by combining Bigfoot Biomedical's smart insulin management systems with its Freestyle Libre technology. Bigfoot Biomedical, a US-based medical technology company, specializes in solutions that integrate with continuous glucose monitoring (CGM) devices.

Major players in the continuous glucose monitoring devices market are Johnson & Johnson, F. Hoffmann-La Roche AG, Sanofi S.A., Abbott Laboratories, Medtronic Public Limited Company, Novo Nordisk A/S, Becton Dickinson and Company, A. Menarini Diagnostics S.r.l., Dexcom Inc., Bionime Corporation, Insulet Corporation, Ascensia Diabetes Care Holdings AG, Tandem Diabetes Care Inc., i-Sens Inc., Senseonics Holdings Inc., Medtrum Technologies Inc., Biolinq Inc., GlySens Incorporated, Glucotrack Inc., Nemaura Medical Inc.

North America was the largest region in the continuous glucose monitoring devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in continuous glucose monitoring devices report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the continuous glucose monitoring devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Continuous glucose monitoring (CGM) devices are used to track blood sugar levels in real time by placing a sensor under the skin. These devices offer continuous data, trend insights, and alerts for both high and low blood sugar levels, which helps manage diabetes more effectively. CGM devices reduce the need for frequent finger pricks and improve glucose control.

The primary components of continuous glucose monitoring devices include transmitters, sensors, and receivers. Transmitters are the components that transmit glucose level data from the sensor to the receiver or connected device for monitoring. They typically connect via Bluetooth or 4G technology. CGM devices are used across various demographics, including both children and adults, for managing conditions such as gestational diabetes, type-1 diabetes, and type-2 diabetes. These devices are utilized in a range of settings, including hospitals, homecare environments, and other healthcare settings.

The continuous glucose monitoring devices market research report is one of a series of new reports that provides continuous glucose monitoring devices market statistics, including the continuous glucose monitoring devices industry global market size, regional shares, competitors with the continuous glucose monitoring devices market share, detailed continuous glucose monitoring devices market segments, market trends, and opportunities, and any further data you may need to thrive in the continuous glucose monitoring devices industry. This continuous glucose monitoring devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The continuous glucose monitoring (CGM) devices include revenues earned by entities by providing services such as real-time glucose monitoring, data sharing, trend analysis, and high or low alerts. The market value includes the value of related goods sold by the service provider or included within the service offering. The continuous glucose monitoring (CGM) devices market also consists of sales of products including dexcom, freestyle libre, medtronic, and eversense. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.